Fabienne McClanahan

1.7k total citations
35 papers, 1.2k citations indexed

About

Fabienne McClanahan is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Fabienne McClanahan has authored 35 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Genetics, 15 papers in Pathology and Forensic Medicine and 15 papers in Immunology. Recurrent topics in Fabienne McClanahan's work include Chronic Lymphocytic Leukemia Research (25 papers), Lymphoma Diagnosis and Treatment (15 papers) and Immune Cell Function and Interaction (9 papers). Fabienne McClanahan is often cited by papers focused on Chronic Lymphocytic Leukemia Research (25 papers), Lymphoma Diagnosis and Treatment (15 papers) and Immune Cell Function and Interaction (9 papers). Fabienne McClanahan collaborates with scholars based in Germany, United Kingdom and United States. Fabienne McClanahan's co-authors include John G. Gribben, John C. Riches, Alan G. Ramsay, Rewas Fatah, Jeffrey K. Davies, Sameena Iqbal, Samir Agrawal, Martina Seiffert, Bola S. Hanna and Peter Lichter and has published in prestigious journals such as Blood, Cancer and Clinical Cancer Research.

In The Last Decade

Fabienne McClanahan

31 papers receiving 1.2k citations

Peers

Fabienne McClanahan
Comparison fields: 5 of 56
  • Genetics 691
  • Immunology 548
  • Oncology 514
  • Pathology and Forensic Medicine 450
  • Hematology 218
Replace MS Tallman with:
MS Tallman United States
Marie‐Christine Kyrtsonis Greece
Mauro Spriano Italy
Maria Stefania De Propris Italy
JP Marolleau France
Monia Lunghi Italy
Antonella Bardi Italy
S. Pileri Italy
Dipti Talaulikar Australia
Paloma Bárcena Spain
MS Tallman United States View profile →
Citations per field, relative to Fabienne McClanahan
Fabienne McClanahan · 1×
Citations per year, relative to Fabienne McClanahan
Fabienne McClanahan · 1×

Countries citing papers authored by Fabienne McClanahan

Since Specialization
Citations

This map shows the geographic impact of Fabienne McClanahan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabienne McClanahan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabienne McClanahan more than expected).

Fields of papers citing papers by Fabienne McClanahan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabienne McClanahan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabienne McClanahan. The network helps show where Fabienne McClanahan may publish in the future.

Co-authorship network of co-authors of Fabienne McClanahan

This figure shows the co-authorship network connecting the top 25 collaborators of Fabienne McClanahan. A scholar is included among the top collaborators of Fabienne McClanahan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fabienne McClanahan. Fabienne McClanahan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
2016 ·Clinical Cancer Research ·Sarah E. M. Herman, Arnau Montraveta, Carsten Utoft Niemann, Helena Mora-Jensen, Michael Gulrajani, Fanny Krantz, Rose Mantel, Lisa L. Smith, Fabienne McClanahan, Bonnie K. Harrington, Dolors Colomer, Todd Covey, John C. Byrd, Raquel Izumi, Allard Kaptein, Roger G. Ulrich, Amy J. Johnson, Brian J. Lannutti, Adrian Wiestner, Jennifer A. Woyach
121
2
Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma
2016 ·BMC Cancer ·Katharina Lisenko, Fabienne McClanahan, Tilman Schöning, (unknown), Martin Cremer, Tobias Dittrich, Anthony D. Ho, Mathias Witzens‐Harig
8
3
Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?
2016 ·Haematologica ·Fabienne McClanahan, Trevor Sharp, John G. Gribben
6
4
Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKC  subversion induces up-regulation of PKC II expression in B lymphocytes
2015 ·Haematologica ·Rinako Nakagawa, (unknown), Anuradha Tarafdar, Emilio Cosimo, Karen Dunn, Alison M. McCaig, (unknown), Fabienne McClanahan, Alan G. Ramsay, John G. Gribben, Alison M. Michie
8
5
Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo
2015 ·Leukemia ·Bola S. Hanna, Fabienne McClanahan, (unknown), Nadja Zaborsky, Verena Kalter, (unknown), Axel Benner, (unknown), Alexander Egle, John G. Gribben, Peter Lichter, Martina Seiffert
101
6
Minimal Renal Toxicity after Rituximab DHAP with a Modified Cisplatin Application Scheme in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma
2015 ·Blood ·Katharina Lisenko, Fabienne McClanahan, Tilman Schöning, (unknown), Martin Cremer, Tobias Dittrich, Anthony D. Ho, Mathias Witzens‐Harig
0
7
Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial
2015 ·British Journal of Haematology ·Mathias Witzens‐Harig, Axel Benner, Fabienne McClanahan, (unknown), (unknown), (unknown), Michael A. Rieger, Julia Meißner, Manfred Hensel, Kai Neben, Peter Dreger, Eva Lengfelder, Ingo Schmidt‐Wolf, Alwin Krämer, Anthony D. Ho
23
8
Transplantation in Chronic Lymphocytic Leukemia
2014 ·Hematology/Oncology Clinics of North America ·Fabienne McClanahan, John G. Gribben
1
9
Aberrant PD-L1 Expression in CLL As a Result of Adaptive Immune Resistance Mediated By Tumor-Secreted Circulating miRNA Binding to Toll-like Receptor 7
2014 ·Blood ·Fabienne McClanahan, Federica Calore, Nicola Zanesi, John G. Gribben, Carlo M. Croce
1
10
T-Cell Dysfunction In CLL Is Mediated Not Only By PD-1/PD-L1 But Also By PD-1/PD-L2 Interactions - Partial Functionality Is Maintained In PD-1 Defined CD8 Subsets and This Can Be Further Promoted By Ibrutinib Treatment
2013 ·Blood ·Fabienne McClanahan, (unknown), John C. Riches, Essam Ghazaly, William Day, Melania Capasso, John G. Gribben
3
11
Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma
2012 ·Cancer ·(unknown), Fabienne McClanahan, Anthony D. Ho, Mathias Witzens‐Harig
35
12
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA STILL A VALID TREATMENT OPTION, OR IS THE GAME OVER ?
2012 ·Mediterranean Journal of Hematology and Infectious Diseases ·Fabienne McClanahan, Peter Dreger
1
13
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial
2012 ·Blood ·Peter Dreger, Hartmut Döhner, Fabienne McClanahan, Raymonde Busch, Matthias Ritgen, Hildegard Greinix, Anna‐Maria Fink, Wolfgang Knauf, Michael Stadler, Michael Pfreundschuh, Ulrich Dührsen, Günter Brittinger, Manfred Hensel, Johannes Schetelig, Dirk Winkler, Andreas Bühler, Michael Kneba, Norbert Schmitz, Michael Hallek, Stephan Stilgenbauer
17
14
Inhibitory Ligands CD200, CD270, CD274 and CD276 Are Expressed On Eμ-TCL1 Transgenic Mouse Splenocytes and Are of Potential Relevance to Impaired T-Cell Function in Vivo
2012 ·Blood ·Fabienne McClanahan, Cristina Ghirelli, Paul Greaves, John C. Riches, Rita Coutinho, Alan G. Ramsay, John G. Gribben
1
15
Diffusion‐weighted imaging for non‐invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology
2011 ·British Journal of Haematology ·Jens Hillengaß, Tobias Bäuerle, Reiner Bartl, Mindaugas Andrulis, Fabienne McClanahan, Frederik B. Laun, Christian M. Zechmann, Rajiv Shah, (unknown), Dirk Simon, Christiane Heiß, Kai Neben, Anthony D. Ho, Heinz‐Peter Schlemmer, (unknown), Stefan Delorme, Bram Stieltjes
106
16
Clinical outcome of patients with follicular lymphoma and bulky disease after Rituximab‐CHOP immunochemotherapy with and without consolidating radiotherapy
2010 ·European Journal Of Haematology ·Fabienne McClanahan, Thomas Hielscher, Michael A. Rieger, Manfred Hensel, Kai Neben, Jens Hillengaß, Klaus Herfarth, Anthony D. Ho, Mathias Witzens‐Harig
6
17
Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial.
2009 ·Blood ·Peter Dreger, Hartmut Döhner, Hildegard Greinix, Fabienne McClanahan, Manfred Hensel, Bernd Hertenstein, Ulrich Dührsen, M. Hentrich, Lorenz Trümper, Ruth Sonnen, Bertold Emmerich, Wolfgang Knauf, Georg Hopfinger, Michael Hallek, Michael Kneba, Norbert Schmitz, Stephan Stilgenbauer
2
18
How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Combined with 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Lymphoma (HD2000-Trial).
2009 ·Blood ·Fabienne McClanahan, Thomas Hielscher, Michael A. Rieger, Manfred Hensel, Martin Bentz, Ingo Schmidt‐Wolf, (unknown), (unknown), Heinz Dürk, (unknown), T E Mandel, Kai Neben, Jens Hillengaß, Anthony D. Ho, Mathias Witzens‐Harig
1
19
Rituximab Maintenenance Therapy in CD20+ B-Cell Non-Hodgkin-Lymphoma – Final Results of a Multicenter Prospective Randomised Phase II Study.
2009 ·Blood ·Mathias Witzens‐Harig, Axel Benner, Michael A. Rieger, Fabienne McClanahan, Manfred Hensel, Kai Neben, Peter Dreger, Eva Lengfelder, Ingo Schmidt‐Wolf, (unknown), Anthony D. Ho
3
20
Long‐term population‐based risks of breast cancer after childhood cancer
2008 ·International Journal of Cancer ·Raoul C. Reulen, Aliki Taylor, D. Winter, Charles Stiller, Clare Frobisher, Emma Lancashire, Fabienne McClanahan, Elaine Sugden, Mike Hawkins, (unknown)
13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by MS Tallman Breakdown of academic impact, for papers by Marie‐Christine Kyrtsonis Breakdown of academic impact, for papers by Mauro Spriano Breakdown of academic impact, for papers by Maria Stefania De Propris Breakdown of academic impact, for papers by JP Marolleau Breakdown of academic impact, for papers by Monia Lunghi Breakdown of academic impact, for papers by Antonella Bardi Breakdown of academic impact, for papers by S. Pileri Breakdown of academic impact, for papers by Dipti Talaulikar Breakdown of academic impact, for papers by Paloma Bárcena
Rankless by CCL
2026